Healthcare Value Capital, LLC
Q1 2014 13F-HR Holdings
Net value change ($000)
+16,582
(12.2%)
New positions
9
Sold out positions
5
Turnover %
43.8%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q4 2013
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| ALBANY MOLECULAR RESH | 8,332 | NEW |
| TEVA | 4,665 | 211.7% |
| PFE | 3,212 | NEW |
| PROSHARES TR | 2,228 | NEW |
| SRNE | 1,282 | NEW |
| SNY | 1,262 | 71.9% |
| PROSHARES TRUST | 1,147 | NEW |
| *BIOTA PHARMACEUTIALS INC | 643 | 75.0% |
| GLMD | 574 | NEW |
| FIBROCELL SCIENCE INC | 564 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| SUPN | -6,969 | -88.0% |
| ANIP | -5,560 | -57.0% |
| FOREST LAB | -4,225 | -100.0% |
| GSK | -2,454 | -100.0% |
| AUXILIUM PHARMACEUTICALS | -2,056 | -29.7% |
| SAGENT PHARMACEUTICALS INC | -1,490 | -100.0% |
| AZN | -1,169 | -23.9% |
| BAX | -655 | -47.1% |
| Kindred Biosciences, Inc. | -559 | -100.0% |
| XENOPORT INC | -443 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
90,161
(59.0% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|